- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04903093
A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.
A PHASE 1, RANDOMIZED, CROSSOVER STUDY TO EVALUATE RELATIVE BIOAVAILABILITY OF ABROCITINIB ORAL SUSPENSION AND EFFECT OF AN ACID-REDUCING AGENT ON THE BIOAVAILABILITY OF ABROCITINIB COMMERCIAL TABLET AND TO ASSESS THE TASTE OF ABROCITINIB ORAL FORMULATIONS IN HEALTHY ADULT PARTICIPANTS AGED 18 TO 55 YEARS OF AGE.
Study Overview
Status
Conditions
Detailed Description
This is a Phase 1 randomized study in healthy participants to estimate the relative bioavailability of abrocitinib oral suspension (Test formulation) compared to commercial abrocitinib tablet (Reference formulation) under fasted condition. The effect of an acid-reducing agent on the pharmacokinetics of the commercial tablet formulation will be evaluated by administering abrocitinib 200 mg commercial tablet with famotidine 40 mg, as an acid-reducing agent. Assessment of taste and palatability of six different abrocitinib suspension formulations will also be performed. This study consists of 2 parts, as listed below:
Part A
Part A of the study will be an open label, randomized, single dose, crossover, 3-treatment, 6 sequence, 3-period design in healthy male and/or female adult participants (18-55 years). Healthy participants will be screened within 28 days prior to the first administration of the study intervention to confirm that they meet the participant selection criteria for the study. Eligible participants will be admitted to the CRU on Day -1 and will be confined in the CRU until discharge, on Day 2 of Period 9 in Part B, after completing both Parts A and B of the study. In Part A, participants will be randomized to receive one of the following: a single 200 mg dose of abrocitinib commercial tablet (Treatment A), a single 200 mg dose of abrocitinib oral suspension formulation 1 (Treatment B), or famotidine (40 mg) administered 120 minutes before a single 200 mg dose of abrocitinib commercial tablet (Treatment C). All participants will be fasting for at least 10 hours before taking abrocitinib.
Part B
Part B will be a single-blind, randomized, 6-period, crossover study in healthy male and/or female adult participants (18-55 years). For any new healthy participants joining Part B only, screening will be performed within 28 days prior to the first administration of the study intervention to confirm that they meet the participant selection criteria for the study. New participants enrolled in Part B only will be admitted to the CRU on Day -1 and will be confined in the CRU until discharge, which is Day 2 of Period 9. On Day 1 of each treatment period under fasted conditions, participants will receive a famotidine tablet (40 mg with 240 mL of room temperature water) administered 120 minutes before a single 200 mg dose of abrocitinib oral suspensions (Formulations 1 to 6) or administered a single 200 mg dose of abrocitinib oral suspension alone (Formulations 1 to 6), after a fast of at least 10 hours before abrocitinib administration.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- New Haven Clinical Research Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female participants who are overtly healthy as determined by medical evaluation including a detailed medical history, complete physical examination, laboratory tests, and cardiovascular tests.
- Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
- Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
- Capable of giving signed informed consent.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- History of human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus infection; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C virus antibody (HCVAb).
- Other acute or chronic medical or psychiatric condition including recent (within the past year).
Evidence or history of clinically significant dermatological condition (eg, atopic dermatitis or psoriasis) or visible rash present during physical examination.
- Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product.
- A positive urine drug test.
- Selected laboratory abnormalities.
- History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
- History of tuberculosis (TB) (active or latent).
- Any history of chronic infections, any history of recurrent infections, any history of latent infections, or any acute infection within 2 weeks of baseline.
- Pregnant female participants; breastfeeding female participants; female participants of childbearing potential who are unwilling or unable to use an acceptable method of contraception.
- History of disseminated herpes zoster, or disseminated herpes simplex, or recurrent localized dermatomal herpes zoster.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A: Abrocitinib Tablet
|
Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.
|
Experimental: Part A: Abrocitinib Suspension F1
|
Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
|
Experimental: Part A: Abrocitinib Tablet + Famotidine
|
Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
|
Experimental: Part B: Abrocitinib Suspension F1
|
Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
|
Experimental: Part B: Abrocitinib Suspension F2
|
Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.
|
Experimental: Part B: Abrocitinib Suspension F3
|
Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.
|
Experimental: Part B: Abrocitinib Suspension F4
|
Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.
|
Experimental: Part B: Abrocitinib Suspension F5
|
Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.
|
Experimental: Part B: Abrocitinib Suspension F6
|
Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.
|
Experimental: Part B: Abrocitinib Suspension F1 + Famotidine
|
Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
|
Experimental: Part B: Abrocitinib Suspension F2 + Famotidine
|
Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.
|
Experimental: Part B: Abrocitinib Suspension F3 + Famotidine
|
Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.
|
Experimental: Part B: Abrocitinib Suspension F4 + Famotidine
|
Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.
|
Experimental: Part B: Abrocitinib Suspension F5 + Famotidine
|
Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.
|
Experimental: Part B: Abrocitinib Suspension F6 + Famotidine
|
Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK parameters of Abrocitinib following the administration of 1x200 mg of abrocitinib tablet (AUCinf)
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞).
|
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
PK parameters of Abrocitinib following the administration of 1x200 mg of abrocitinib tablet (Cmax)
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
Maximum observed plasma concentration.
|
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
PK parameters of Abrocitinib following the administration of 1×200 mg of abrocitinib tablet with famotidine 40 mg in Part A (AUCinf)
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞).
|
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
PK parameters of Abrocitinib following the administration of 1×200 mg of abrocitinib tablet with famotidine 40 mg in Part A (Cmax)
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
Maximum observed plasma concentration.
|
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
PK parameters of Abrocitinib following the administration of 200 mg of abrocitinib oral suspension F1 (AUCinf)
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞).
|
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
PK parameters of Abrocitinib following the administration of 200 mg of abrocitinib oral suspension F1 (Cmax)
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
Maximum observed plasma concentration.
|
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
Number of subjects reporting overall liking after administering each abrocitinib oral suspension formulation (F1-F6) in Part B
Time Frame: 1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)
|
Overall liking assesses the degree that a participant likes a drug formulation based on sensory attributes experienced by the participant after tasting a product.
It is scored based on a measurement of taste questionnaire.
|
1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)
|
Number of subjects reporting mouth feel after administering each abrocitinib oral suspension formulation (F1-F6) in Part B
Time Frame: 1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)
|
Mouth feel assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation.
It is scored based on a measurement of taste questionnaire.
|
1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)
|
Number of subjects reporting bitterness after administering each abrocitinib oral suspension formulation (F1-F6) in Part B
Time Frame: 1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)
|
Bitterness assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation.
It is scored based on a measurement of taste questionnaire.
|
1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)
|
Number of subjects reporting tongue/mouth after administering each abrocitinib oral suspension formulation (F1-F6) in Part B
Time Frame: 1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)
|
Tongue/mouth burn assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation.
It is scored based on a measurement of taste questionnaire.
|
1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)
|
Number of subjects reporting salty taste after administering each abrocitinib oral suspension formulation (F1-F6) in Part B
Time Frame: 1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)
|
Salty taste assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation.
It is scored based on a measurement of taste questionnaire.
|
1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)
|
Number of subjects reporting sour taste after administering abrocitinib oral suspension formulation (F1-F6) in Part B
Time Frame: 1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulations (F1-F6)
|
Sour taste assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation.
It is scored based on a measurement of taste questionnaire.
|
1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulations (F1-F6)
|
Number of subjects reporting sweet taste after administering abrocitinib oral suspension formulation (F1-F6) in Part B
Time Frame: 1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)
|
Sweet taste assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation.
It is scored based on a measurement of taste questionnaire.
|
1 (immediately after dosing), 5, 10, and 20 minutes after administering each abrocitinib oral suspension formulation (F1-F6)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK parameters of metabolites (M1, M2 and M4) following the administration of 1×200 mg of abrocitinib tablet with or without famotidine 40 mg in Part A (AUCinf)
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞).
|
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
PK parameters of metabolites (M1, M2 and M4) following the administration of 1×200 mg of abrocitinib tablet with or without famotidine 40 mg in Part A (Cmax)
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
Maximum observed plasma concentration.
|
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose
|
Number of subjects with treatment-emergent adverse event in Part A and Part B of the study
Time Frame: Baseline until Period 9 study day 2
|
Baseline until Period 9 study day 2
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B7451061
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Abrocitinib tablet
-
Innovaderm Research Inc.Not yet recruiting
-
National Institute of Diabetes and Digestive and...PfizerRecruitingDiabetes Mellitus, Type 1United States
-
PfizerActive, not recruitingAtopic DermatitisIndia
-
PfizerActive, not recruitingDermatitis, AtopicChina, United States, Spain, Taiwan, Germany, Australia, Canada, Hungary, Korea, Republic of, Poland, Serbia, Bulgaria, Czechia, Japan, Latvia, United Kingdom, Belgium, Israel, Italy, Finland, Mexico, Romania, Slovakia, Argentina, Brazil, Chil... and more
-
PfizerAvailableAtopic DermatitisTaiwan, United States, Australia, Austria, Belgium, Canada, Greece, Mexico, Netherlands, Russian Federation, Spain, Switzerland
-
William DamskyYale University; PfizerActive, not recruiting
-
PfizerIn Expanded Access, treating physicians are the SponsorAvailableSevere Uncontrolled Atopic Dermatitis
-
PfizerCompletedAtopic DermatitisSpain, Taiwan, United States, Korea, Republic of, Poland, Canada, Australia, Hungary, Germany, Latvia, Finland, Chile, Bulgaria, Slovakia, Italy
-
Icahn School of Medicine at Mount SinaiRecruiting